Immusoft

Executive Summary

Immusoft is pioneering a novel cell therapy platform called Immune System Programming (ISP), which engineers a patient's own B cells to serve as sustained biofactories for therapeutic protein delivery. Unlike traditional gene therapies that target short-lived cells, B cells can persist for years and be re-dosed, potentially offering durable, long-term treatment for chronic diseases. The company's approach involves collecting B cells, programming them ex vivo to produce a therapeutic protein, and reinfusing them to continuously secrete the protein in the body. This platform has broad applicability across multiple therapeutic areas, including enzyme deficiencies, metabolic disorders, and autoimmune diseases. Immusoft's lead program targets mucopolysaccharidosis type I (MPS I), a rare lysosomal storage disease, and aims to overcome limitations of current enzyme replacement therapies by providing a lifelong, single-dose solution. Founded in 1986 and based in Seattle, Immusoft has been privately funded and is currently in the pre-clinical stage. The company has conducted extensive preclinical studies demonstrating proof-of-concept, including sustained protein expression and disease correction in animal models. Immusoft is now advancing toward regulatory filing and expects to initiate first-in-human clinical trials in the near term. The global cell therapy market is projected to exceed $50 billion by 2030, and Immusoft's unique B-cell platform positions it as a potential leader in next-generation gene and cell therapies. However, being pre-clinical, the company faces significant technical and regulatory risks. With a seasoned management team and strong IP portfolio, Immusoft represents a high-risk, high-reward opportunity in the biotechnology sector.

Upcoming Catalysts (preview)

• Q1 2027IND Submission for ISP-001 in MPS I40% success
• Q4 2026Announcement of Strategic Partnership or Licensing Deal30% success
• Q2 2027Series B Financing Round50% success